Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system
This study highlights the importance of monitoring for GBS symptoms following the administration of certain medications, particularly those that affect immune function, and underscores the need for healthcare providers to be aware of the potential neurological risks associated with these medications.
Authors
- Rujia Zhong (ORCID: https://orcid.org/0000-0002-6131-2660)
- Yi Guo (ORCID: https://orcid.org/0000-0002-7158-351X)
- Jiahao Li (ORCID: https://orcid.org/0000-0002-5967-5518)
- Feng Zhang (ORCID: https://orcid.org/0000-0001-9401-4339)
Institutions
- University of Groningen (NL)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1080/14740338.2025.2493781
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China